Comparative Pharmacology
Head-to-head clinical analysis: DILAUDID versus ROXYBOND.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILAUDID versus ROXYBOND.
DILAUDID vs ROXYBOND
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dilaudid (hydromorphone) is a full opioid agonist with high affinity for mu-opioid receptors, producing analgesia by mimicking endogenous endorphins and enkephalins. It also activates kappa and delta opioid receptors to a lesser extent.
ROXYBOND is an immediate-release formulation of oxycodone, a full mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception and emotional response to pain.
Initial: 2-4 mg orally every 4-6 hours as needed; or 1-2 mg intramuscularly, subcutaneously, or intravenously every 4-6 hours as needed.
Immediate-release oral tablets: 5-15 mg every 4-6 hours as needed for pain. Maximum 60 mg/day. For extended-release: 10-20 mg every 12 hours, adjusted based on prior opioid use.
None Documented
None Documented
2.5-3.5 hours (terminal); prolonged in hepatic/renal impairment
3.5–6 hours; prolonged in renal impairment, hepatic impairment, or elderly patients, requiring dose adjustment.
Primarily renal (90% as hydromorphone-3-glucuronide and parent drug); <1% biliary/fecal
Primarily renal (90% as free drug and glucuronide conjugates). Fecal elimination accounts for <10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic